Literature DB >> 8053024

Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives.

N J White1.   

Abstract

Reliable and reproducible methods for the measurements of artemisinin and its derivatives in body fluids have proved difficult to develop. The available evidence suggests that all compounds are hydrolysed to a biologically active metabolite, dihydroartemisinin, which is eliminated rapidly. The role of other (hydroxylated) metabolites in humans requires further study. The hydrolysis of artesunate is so rapid that it may be considered a pro-drug for dihydroartemisinin. All the artemisinin compounds induce more rapid reduction of parasitaemia than other antimalarial drugs, indicating a direct effect on ring forms. This pharmacodynamic measure can be used in drug comparisons, and allows estimations of the number of parasites removed before sequestration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053024     DOI: 10.1016/0035-9203(94)90471-5

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  45 in total

1.  Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.

Authors:  Grace O Gbotosho; Akintunde Sowunmi; Christian T Happi; Titilope M Okuboyejo
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

3.  Nonisotopic, semiautomated plasmodium falciparum bioassay for measurement of antimalarial drug levels in serum or plasma.

Authors:  Harald Noedl; Paktiya Teja-Isavadharm; Robert Scott Miller
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

5.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

6.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

7.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 8.  New antimalarials. A risk-benefit analysis.

Authors:  F Nosten; R N Price
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 9.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

10.  In vivo parasitological measures of artemisinin susceptibility.

Authors:  Kasia Stepniewska; Elizabeth Ashley; Sue J Lee; Nicholas Anstey; Karen I Barnes; Tran Quang Binh; Umberto D'Alessandro; Nicholas P J Day; Peter J de Vries; Grant Dorsey; Jean-Paul Guthmann; Mayfong Mayxay; Paul N Newton; Piero Olliaro; Lyda Osorio; Ric N Price; Mark Rowland; Frank Smithuis; Walter R J Taylor; François Nosten; Nicholas J White
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.